Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-001 (Biocure Technology)
- Development stage
- Unknown
- Lead developer
- BiocurePharm
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BP-001 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen, which is expressed on the surface of most B-cell lineage malignancies. Developed by BiocurePharm, a subsidiary of Biocure Technology, the therapy involves the ex vivo genetic modification of a patient's T-cells to express a CAR specific for CD19. Once re-infused into the patient, these engineered T-cells identify and destroy CD19-positive malignant B-cells. BP-001 is being investigated for the treatment of B-cell cancers, specifically Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL), and has advanced into clinical development in South Korea following IND approval.
- Other names
- anti-CD19 CAR-T cell therapy (BiocurePharm)Biocure CD19 CAR-T
02
Targets
Beyond the preview
Go deeper on BP-001 (Biocure Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-001 (Biocure Technology).